Metastatic dormancy: A complex network between cancer stem cells and their microenvironment

Histology and Histopathology

Volumn 29, Issue 12, 2014, Pages 1499-1510

  Bleau, Anne Marie ^a   Agliano, Alice ^b   Larzabal, Leyre ^a   de Aberasturi, Arrate Lopez ^a,c   Calvo, Alfonso ^a,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Extracellular matrix; Metastatic niche; Therapy resistance

Indexed keywords

CANCER STEM CELL; HUMAN; METASTASIS; NEOPLASM; PATHOLOGY; PHYSIOLOGY; TUMOR INVASION; TUMOR MICROENVIRONMENT;

HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC STEM CELLS; TUMOR MICROENVIRONMENT;

EID: 84912559867     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. Aguirre-Ghiso J.A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7, 834-846.
2. Aguirre-Ghiso J.A., Bragado P. and Sosa M.S. (2013). Metastasis awakening: Targeting dormant cancer. Nat. Med. 19, 276-277.
3. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J. and Clarke M.F. (2003). Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 3983-3988.
4. Alix-Panabieres C. and Pantel K. (2014). Technologies for detection of circulating tumor cells: Facts and vision. Lab. Chip 14, 57-62.
5. Allgayer H. and Aguirre-Ghiso J.A. (2008). The urokinase receptor (upar)-- a link between tumor cell dormancy and minimal residual disease in bone marrow? APMIS 116, 602-614.
6. Alvero A.B., Chen R., Fu H.H., Montagna M., Schwartz P.E., Rutherford T., Silasi D.A., Steffensen K.D., Waldstrom M., Visintin I. and Mor G. (2009). Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 8, 158-166.
7. Avivar-Valderas A., Bobrovnikova-Marjon E., Alan Diehl J., Bardeesy N., Debnath J. and Aguirre-Ghiso J.A. (2013). Regulation of autophagy during ecm detachment is linked to a selective inhibition of mtorc1 by perk. Oncogene 32, 4932-4940.
8. Baccelli I., Schneeweiss A., Riethdorf S., Stenzinger A., Schillert A., Vogel V., Klein C., Saini M., Bauerle T., Wallwiener M., Holland-Letz T., Hofner T., Sprick M., Scharpff M., Marme F., Sinn H.P., Pantel K., Weichert W. and Trumpp A. (2013). Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat. Biotechnol. 31, 539- 544.
9. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D. and Rich J.N. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760.
10. Barkan D., Kleinman H., Simmons J.L., Asmussen H., Kamaraju A.K., Hoenorhoff M.J., Liu Z.Y., Costes S.V., Cho E.H., Lockett S., Khanna C., Chambers A.F. and Green J.E. (2008). Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res. 68, 6241-6250.
11. Bellizzi A., Sebastian S., Ceglia P., Centonze M., Divella R., Manzillo E.F., Azzariti A., Silvestris N., Montemurro S., Caliandro C., De Luca R., Cicero G., Rizzo S., Russo A., Quaranta M., Simone G. and Paradiso A. (2013). Co-expression of cd133(+)/cd44(+) in human colon cancer and liver metastasis. J. Cell. Physiol. 228, 408-415.
12. Bergers G. and Benjamin L.E. (2003). Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401-410.
13. Bertolini G., Roz L., Perego P., Tortoreto M., Fontanella E., Gatti L., Pratesi G., Fabbri A., Andriani F., Tinelli S., Roz E., Caserini R., Lo Vullo S., Camerini T., Mariani L., Delia D., Calabro E., Pastorino U. and Sozzi G. (2009). Highly tumorigenic lung cancer cd133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. USA 106, 16281-16286.
14. Bleau A.M., Huse J.T. and Holland E.C. (2009a). The abcg2 resistance network of glioblastoma. Cell Cycle 8, 2936-2944.
15. Bleau A.M., Hambardzumyan D., Ozawa T., Fomchenko E.I., Huse J.T., Brennan C.W. and Holland E.C. (2009b). Pten/pi3k/akt pathway regulates the side population phenotype and abcg2 activity in glioma tumor stem-like cells. Cell Stem Cell 4, 226-235.
16. Bleau A., Freire F., Pajares M.J., Zudaire I., Anton I., Nistal-Villán E., Redrado M., Garmendia I., Ajona D., Blanco D., Pio R., Lecanda F., Calvo A. and Montuenga L. (2014). New syngeneic inflammatoryrelated lung cancer metastatic model harboring double kras/wwox alterations. Int. J. Cancer (Accepted Article).
17. Bonnet D. and Dick J.E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737.
18. Borovski T., De Sousa E.M.F., Vermeulen L. and Medema J.P. (2011). Cancer stem cell niche: The place to be. Cancer Res. 71, 634-639.
19. Boyerinas B., Zafrir M., Yesilkanal A.E., Price T.T., Hyjek E.M. and Sipkins D.A. (2013). Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. Blood 121, 4821-4831.
20. Bragado P., Sosa M.S., Keely P., Condeelis J. and Aguirre-Ghiso J.A. (2012). Microenvironments dictating tumor cell dormancy. Recent Results Cancer Res. 195, 25-39.
21. Bragado P., Estrada Y., Parikh F., Krause S., Capobianco C., Farina H.G., Schewe D.M. and Aguirre-Ghiso J.A. (2013). Tgf-beta2 dictates disseminated tumour cell fate in target organs through tgfbeta- riii and p38alpha/beta signalling. Nat. Cell. Biol. 15, 1351-1361.
22. Brescia P., Richichi C. and Pelicci G. (2012). Current strategies for identification of glioma stem cells: Adequate or unsatisfactory? J. Oncol. 2012, 376894.
23. Budd G.T., Cristofanilli M., Ellis M.J., Stopeck A., Borden E., Miller M.C., Matera J., Repollet M., Doyle G.V., Terstappen L.W. and Hayes D.F. (2006). Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 12, 6403- 6409.
24. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., Oh E.Y., Gaber M.W., Finklestein D., Allen M., Frank A., Bayazitov I.T., Zakharenko S.S., Gajjar A., Davidoff A. and Gilbertson R.J. (2007). A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69-82.
25. Chaffer C.L. and Weinberg R.A. (2011). A perspective on cancer cell metastasis. Science 331, 1559-1564.
26. Chang H.Y., Nuyten D.S., Sneddon J.B., Hastie T., Tibshirani R., Sorlie T., Dai H., He Y.D., van't Veer L.J., Bartelink H., van de Rijn M., Brown P.O. and van de Vijver M.J. (2005). Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl. Acad. Sci. USA 102, 3738-3743.
27. Charafe-Jauffret E., Ginestier C., Iovino F., Tarpin C., Diebel M., Esterni B., Houvenaeghel G., Extra J.M., Bertucci F., Jacquemier J., Xerri L., Dontu G., Stassi G., Xiao Y., Barsky S.H., Birnbaum D., Viens P. and Wicha M.S. (2010). Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin. Cancer Res. 16, 45-55.
28. Cheng L., Huang Z., Zhou W., Wu Q., Donnola S., Liu J.K., Fang X., Sloan A.E., Mao Y., Lathia J.D., Min W., McLendon R.E., Rich J.N. and Bao S. (2013). Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153, 139-152.
29. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., Visvader J., Weissman I.L. and Wahl G.M. (2006). Cancer stem cells--perspectives on current status and future directions: Aacr workshop on cancer stem cells. Cancer Res. 66, 9339-9344.
30. Correa R.J., Peart T., Valdes Y.R., DiMattia G.E. and Shepherd T.G. (2012). Modulation of akt activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids. Carcinogenesis 33, 49-58.
31. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., Reuben J.M., Doyle G.V., Allard W.J., Terstappen L.W. and Hayes D.F. (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781-791.
32. Dalerba P., Dylla S.J., Park I.K., Liu R., Wang X., Cho R.W., Hoey T., Gurney A., Huang E.H., Simeone D.M., Shelton A.A., Parmiani G., Castelli C. and Clarke M.F. (2007). Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 104, 10158-10163.
33. Danila D.C., Fleisher M. and Scher H.I. (2011). Circulating tumor cells as biomarkers in prostate cancer. Clin. Cancer Res. 17, 3903-3912.
34. Desgrosellier J.S. and Cheresh D.A. (2010). Integrins in cancer: Biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9-22.
35. Diehn M. and Majeti R. (2010). Metastatic cancer stem cells: An opportunity for improving cancer treatment? Cell Stem Cell 6, 502- 503.
36. Early Breast Cancer Trialists Collaborative Group (EBCTCG). (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365, 1687-1717.
37. El Touny L.H., Vieira A., Mendoza A., Khanna C., Hoenerhoff M.J. and Green J.E. (2014). Combined sfk/mek inhibition prevents metastatic outgrowth of dormant tumor cells. J. Clin. invest. 124, 156-168.
38. Fillmore C.M. and Kuperwasser C. (2008). Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 10, R25.
39. Fung C., Lock R., Gao S., Salas E. and Debnath J. (2008). Induction of autophagy during extracellular matrix detachment promotes cell survival. Mol. Biol. Cell 19, 797-806.
40. Galimberti V. and Cole B.F. (2013). Axillary versus sentinel-lymph-node dissection for micrometastatic breast cancer--authors' reply. Lancet Oncol.14, e251-252.
41. Gao H., Chakraborty G., Lee-Lim A.P., Mo Q., Decker M., Vonica A., Shen R., Brogi E., Brivanlou A.H. and Giancotti F.G. (2012). The bmp inhibitor coco reactivates breast cancer cells at lung metastatic sites. Cell 150, 764-779.
42. Giancotti F.G. (2013). Mechanisms governing metastatic dormancy and reactivation. Cell 155, 750-764.
43. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M.S. and Dontu G. (2007). Aldh1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567.
44. Giordano A., Gao H., Anfossi S., Cohen E., Mego M., Lee B.N., Tin S., De Laurentiis M., Parker C.A., Alvarez R.H., Valero V., Ueno N.T., De Placido S., Mani S.A., Esteva F.J., Cristofanilli M. and Reuben J.M. (2012). Epithelial-mesenchymal transition and stem cell markers in patients with her2-positive metastatic breast cancer. Mol. Cancer Therap. 11, 2526-2534.
45. Goss P.E. and Chambers A.F. (2010). Does tumour dormancy offer a therapeutic target? Nat. Rev. Cancer 10, 871-877.
46. Gottschling S., Schnabel P.A., Herth F.J. and Herpel E. (2012). Are we missing the target? Cancer stem cells and drug resistance in nonsmall cell lung cancer. Cancer Genom. Proteom. 9, 275-286.
47. Gupta G.P. and Massague J. (2006). Cancer metastasis: Building a framework. Cell 127, 679-695.
48. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A. and Lander E.S. (2009). Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645-659.
49. Han J., Hou W., Goldstein L.A., Lu C., Stolz D.B., Yin X.M. and Rabinowich H. (2008). Involvement of protective autophagy in trail resistance of apoptosis-defective tumor cells. J. Biol. Chem. 283, 19665-19677.
50. Haraguchi N., Ishii H., Mimori K., Tanaka F., Ohkuma M., Kim H.M., Akita H., Takiuchi D., Hatano H., Nagano H., Barnard G.F., Doki Y. and Mori M. (2010). Cd13 is a therapeutic target in human liver cancer stem cells. J. Clin. Invest. 120, 3326-3339.
51. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J. and Heeschen C. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313-323.
52. Hiraga T., Ito S. and Nakamura H. (2013). Cancer stem-like cell marker cd44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res. 73, 4112-4122.
53. Hurt E.M., Kawasaki B.T., Klarmann G.J., Thomas S.B. and Farrar W.L. (2008). Cd44+ cd24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br. J. Cancer 98, 756-765.
54. Hussein O. and Komarova S.V. (2011). Breast cancer at bone metastatic sites: Recent discoveries and treatment targets. J. Cell. Commun. Signal 5, 85-99.
55. Jamieson C.H., Ailles L.E., Dylla S.J., Muijtjens M., Jones C., Zehnder J.L., Gotlib J., Li K., Manz M.G., Keating A., Sawyers C.L. and Weissman I.L. (2004). Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis cml. New England J. Med. 351, 657-667.
56. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F. and Dick J.E. (2006). Targeting of cd44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12, 1167-1174.
57. Jordan C.T. (2009). Cancer stem cells: Controversial or just misunderstood? Cell Stem Cell 4, 203-205.
58. Kang S.Y. and Watnick R.S. (2008). Regulation of tumor dormancy as a function of tumor-mediated paracrine regulation of stromal tsp-1 and vegf expression. APMIS 116, 638-647.
59. Kim J.K., Jung Y., Wang J., Joseph J., Mishra A., Hill E.E., Krebsbach P.H., Pienta K.J., Shiozawa Y. and Taichman R.S. (2013). Tbk1 regulates prostate cancer dormancy through mtor inhibition. Neoplasia 15, 1064-1074.
60. Konopleva M., Zhao S., Hu W., Jiang S., Snell V., Weidner D., Jackson C.E., Zhang X., Champlin R., Estey E., Reed J.C. and Andreeff M. (2002). The anti-apoptotic genes bcl-x(l) and bcl-2 are overexpressed and contribute to chemoresistance of non-proliferating leukaemic cd34+ cells. Br. J. Haematol. 118, 521-534.
61. Krivtsov A.V., Twomey D., Feng Z., Stubbs M.C., Wang Y., Faber J., Levine J.E., Wang J., Hahn W.C., Gilliland D.G., Golub T.R. and Armstrong S.A. (2006). Transformation from committed progenitor to leukaemia stem cell initiated by mll-af9. Nature 442, 818-822.
62. Krock B.L., Skuli N. and Simon M.C. (2011). Hypoxia-induced angiogenesis: Good and evil. Genes Cancer 2, 1117-1133.
63. Kumar D., Shankar S. and Srivastava R.K. (2013). Rottlerin-induced autophagy leads to the apoptosis in breast cancer stem cells: Molecular mechanisms. Mol. Cancer 12, 171.
64. Lagadinou E.D., Sach A., Callahan K., Rossi R.M., Neering S.J., Minhajuddin M., Ashton J.M., Pei S., Grose V., O'Dwyer K.M., Liesveld J.L., Brookes P.S., Becker M.W. and Jordan C.T. (2013). Bcl-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12, 329-341.
65. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres- Cortes J., Minden M., Paterson B., Caligiuri M.A. and Dick J.E. (1994). A cell initiating human acute myeloid leukaemia after transplantation into scid mice. Nature 367, 645-648.
66. Larzabal L., El-Nikhely N., Redrado M., Seeger W., Savai R. and Calvo A. (2013). Differential effects of drugs targeting cancer stem cell (csc) and non-csc populations on lung primary tumors and metastasis. PLoS One 8, e79798.
67. Lecharpentier A., Vielh P., Perez-Moreno P., Planchard D., Soria J.C. and Farace F. (2011). Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br. J. Cancer 105, 1338-1341.
68. Leversha M.A., Han J., Asgari Z., Danila D.C., Lin O., Gonzalez- Espinoza R., Anand A., Lilja H., Heller G., Fleisher M. and Scher H.I. (2009). Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin. Cancer Res. 15, 2091-2097.
69. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F. and Simeone D.M. (2007). Identification of pancreatic cancer stem cells. Cancer Res. 67, 1030-1037.
70. Liu H., Patel M.R., Prescher J.A., Patsialou A., Qian D., Lin J., Wen S., Chang Y.F., Bachmann M.H., Shimono Y., Dalerba P., Adorno M., Lobo N., Bueno J., Dirbas F.M., Goswami S., Somlo G., Condeelis J., Contag C.H., Gambhir S.S. and Clarke M.F. (2010). Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc. Natl. Acad. Sci. USA 107, 18115-18120.
71. Lu K.V., Chang J.P., Parachoniak C.A., Pandika M.M., Aghi M.K., Meyronet D., Isachenko N., Fouse S.D., Phillips J.J., Cheresh D.A., Park M. and Bergers G. (2012). Vegf inhibits tumor cell invasion and mesenchymal transition through a met/vegfr2 complex. Cancer Cell 22, 21-35.
72. Lu X., Mu E., Wei Y., Riethdorf S., Yang Q., Yuan M., Yan J., Hua Y., Tiede B.J., Haffty B.G., Pantel K., Massague J. and Kang Y. (2011). Vcam-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell 20, 701-714.
73. Ma I. and Allan A.L. (2011). The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev. 7, 292-306.
74. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J. and Weinberg R.A. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715.
75. Marcato P., Dean C.A., Pan D., Araslanova R., Gillis M., Joshi M., Helyer L., Pan L., Leidal A., Gujar S., Giacomantonio C.A. and Lee P.W. (2011). Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform aldh1a3 and its expression is predictive of metastasis. Stem Cells 29, 32-45.
76. Marlow R., Honeth G., Lombardi S., Cariati M., Hessey S., Pipili A., Mariotti V., Buchupalli B., Foster K., Bonnet D., Grigoriadis A., Rameshwar P., Purushotham A., Tutt A. and Dontu G. (2013). A novel model of dormancy for bone metastatic breast cancer cells. Cancer Res. 73, 6886-6899.
77. Martin-Padura I., Marighetti P., Agliano A., Colombo F., Larzabal L., Redrado M., Bleau A.M., Prior C., Bertolini F. and Calvo A. (2012). Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab. Invest. 92, 952-966.
78. Meng S., Tripathy D., Frenkel E.P., Shete S., Naftalis E.Z., Huth J.F., Beitsch P.D., Leitch M., Hoover S., Euhus D., Haley B., Morrison L., Fleming T.P., Herlyn D., Terstappen L.W., Fehm T., Tucker T.F., Lane N., Wang J. and Uhr J.W. (2004). Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 10, 8152- 8162.
79. Meng R.D., Shelton C.C., Li Y.M., Qin L.X., Notterman D., Paty P.B. and Schwartz G.K. (2009). Gamma-secretase inhibitors abrogate oxaliplatin-induced activation of the notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res. 69, 573-582.
80. Miyamoto D.T., Lee R.J., Stott S.L., Ting D.T., Wittner B.S., Ulman M., Smas M.E., Lord J.B., Brannigan B.W., Trautwein J., Bander N.H., Wu C.L., Sequist L.V., Smith M.R., Ramaswamy S., Toner M., Maheswaran S. and Haber D.A. (2012). Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discovery 2, 995-1003.
81. Mu X., Isaac C., Greco N., Huard J. and Weiss K. (2013). Notch signaling is associated with aldh activity and an aggressive metastatic phenotype in murine osteosarcoma cells. Front. Oncol. 3, 143.
82. Mukhopadhyay S., Panda P.K., Sinha N., Das D.N. and Bhutia S.K. (2014). Autophagy and apoptosis: Where do they meet? Apoptosis 19, 555-566.
83. Naumov G.N., Akslen L.A. and Folkman J. (2006). Role of angiogenesis in human tumor dormancy: Animal models of the angiogenic switch. Cell Cycle 5, 1779-1787.
84. Naumov G.N., Townson J.L., MacDonald I.C., Wilson S.M., Bramwell V.H., Groom A.C. and Chambers A.F. (2003). Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res. Treat. 82, 199- 206.
85. Nechemia-Arbely Y., Barkan D., Pizov G., Shriki A., Rose-John S., Galun E. and Axelrod J.H. (2008). Il-6/il-6r axis plays a critical role in acute kidney injury. J. Am. Soc. Nephrol. 19, 1106-1115.
86. Nguyen D.X., Bos P.D. and Massague J. (2009). Metastasis: From dissemination to organ-specific colonization. Nat. Rev. Cancer 9, 274-284.
87. Noda T., Nagano H., Takemasa I., Yoshioka S., Murakami M., Wada H., Kobayashi S., Marubashi S., Takeda Y., Dono K., Umeshita K., Matsuura N., Matsubara K., Doki Y., Mori M. and Monden M. (2009). Activation of wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br. J. Cancer 100, 1647-1658.
88. Nowell P.C. (1976). The clonal evolution of tumor cell populations. Science 194, 23-28.
89. Paez D., Labonte M.J., Bohanes P., Zhang W., Benhanim L., Ning Y., Wakatsuki T., Loupakis F. and Lenz H.J. (2012). Cancer dormancy: A model of early dissemination and late cancer recurrence. Clin. Cancer Res. 18, 645-653.
90. Paget S. (1989). The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev. 8, 98-101.
91. Pang R., Law W.L., Chu A.C., Poon J.T., Lam C.S., Chow A.K., Ng L., Cheung L.W., Lan X.R., Lan H.Y., Tan V.P., Yau T.C., Poon R.T. and Wong B.C. (2010). A subpopulation of cd26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 6, 603-615.
92. Pantel K., Alix-Panabieres C. and Riethdorf S. (2009). Cancer micrometastases. Nat. Rev. Clin. Oncol. 6, 339-351.
93. Passegue E., Wagner E.F. and Weissman I.L. (2004). Junb deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 119, 431-443.
94. Psaila B. and Lyden D. (2009). The metastatic niche: Adapting the foreign soil. Nat. Rev. Cancer 9, 285-293.
95. Rack B., Bock C., Andergassen U. and Doisneau-Sixou S. (2012). Hormone receptor status, erbb2 expression and cancer stem cell characteristics of circulating tumor cells in breast cancer patients. Histol. Histopathol. 27, 855-864.
96. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C. and De Maria R. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111-115.
97. Roodman G.D. (2012). Genes associate with abnormal bone cell activity in bone metastasis. Cancer Metastasis Rev. 31, 569-578.
98. Schafer A., Teufel J., Ringel F., Bettstetter M., Hoepner I., Rasper M., Gempt J., Koeritzer J., Schmidt-Graf F., Meyer B., Beier C.P. and Schlegel J. (2012). Aldehyde dehydrogenase 1a1--a new mediator of resistance to temozolomide in glioblastoma. Neuro Oncol. 14, 1452-1464.
99. Scheel C., Eaton E.N., Li S.H., Chaffer C.L., Reinhardt F., Kah K.J., Bell G., Guo W., Rubin J., Richardson A.L. and Weinberg R.A. (2011). Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145, 926-940.
100. Scheel C. and Weinberg R.A. (2012). Cancer stem cells and epithelialmesenchymal transition: Concepts and molecular links. Semin Cancer Biol. 22, 396-403.
101. Scher H.I., Jia X., de Bono J.S., Fleisher M., Pienta K.J., Raghavan D. and Heller G. (2009). Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: A reanalysis of immc38 trial data. Lancet Oncol. 10, 233-239.
102. Shibue T., Brooks M.W., Inan M.F., Reinhardt F. and Weinberg R.A. (2012). The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions. Cancer Discov. 2, 706-721.
103. Shuman Moss L.A., Jensen-Taubman S. and Stetler-Stevenson W.G. (2012). Matrix metalloproteinases: Changing roles in tumor progression and metastasis. Am. J. Pathol. 181, 1895-1899.
104. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J. and Dirks P.B. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821-5828.
105. Singh A. and Settleman J. (2010). Emt, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene 29, 4741-4751.
106. Sosa M.S., Bragado P., Debnath J. and Aguirre-Ghiso J.A. (2013). Regulation of tumor cell dormancy by tissue microenvironments and autophagy. Adv. Exp. Med. Biol. 734, 73-89.
107. Steeg P.S. (2006). Tumor metastasis: Mechanistic insights and clinical challenges. Nat. Med. 12, 895-904.
108. Sullivan J.P., Spinola M., Dodge M., Raso M.G., Behrens C., Gao B., Schuster K., Shao C., Larsen J.E., Sullivan L.A., Honorio S., Xie Y., Scaglioni P.P., DiMaio J.M., Gazdar A.F., Shay J.W., Wistuba, II and Minna J.D. (2010). Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 70, 9937-9948.
109. Sun Y., Campisi J., Higano C., Beer T.M., Porter P., Coleman I., True L. and Nelson P.S. (2012). Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through wnt16b. Nat. Med. 18, 1359-1368.
110. Tanei T., Morimoto K., Shimazu K., Kim S.J., Tanji Y., Taguchi T., Tamaki Y. and Noguchi S. (2009). Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res. 15, 4234- 4241.
111. Taussig D.C., Miraki-Moud F., Anjos-Afonso F., Pearce D.J., Allen K., Ridler C., Lillington D., Oakervee H., Cavenagh J., Agrawal S.G., Lister T.A., Gribben J.G. and Bonnet D. (2008). Anti-cd38 antibodymediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 112, 568-575.
112. Teicher B.A. and Fricker S.P. (2010). Cxcl12 (sdf-1)/cxcr4 pathway in cancer. Clin. Cancer Res. 16, 2927-2931.
113. Tirino V., Desiderio V., Paino F., De Rosa A., Papaccio F., La Noce M., Laino L., De Francesco F. and Papaccio G. (2013). Cancer stem cells in solid tumors: An overview and new approaches for their isolation and characterization. FASEB J. 27, 13-24.
114. Tlsty T.D. and Coussens L.M. (2006). Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 1, 119-150.
115. Tran D.D., Corsa C.A., Biswas H., Aft R.L. and Longmore G.D. (2011). Temporal and spatial cooperation of snail1 and twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence. Mol. Cancer Res. 9, 1644-1657.
116. Ulasov I.V., Nandi S., Dey M., Sonabend A.M. and Lesniak M.S. (2011). Inhibition of sonic hedgehog and notch pathways enhances sensitivity of cd133(+) glioma stem cells to temozolomide therapy. Mol. Med. 17, 103-112.
117. Valastyan S. and Weinberg R.A. (2011). Tumor metastasis: Molecular insights and evolving paradigms. Cell 147, 275-292.
118. Vinogradov S. and Wei X. (2012). Cancer stem cells and drug resistance: The potential of nanomedicine. Nanomedicine (Lond) 7, 597-615.
119. Visus C., Wang Y., Lozano-Leon A., Ferris R.L., Silver S., Szczepanski M.J., Brand R.E., Ferrone C.R., Whiteside T.L., Ferrone S., DeLeo A.B. and Wang X. (2011). Targeting aldh(bright) human carcinomainitiating cells with aldh1a1-specific cd8(+) t cells. Clin. Cancer Res. 17, 6174-6184.
120. White A.C., Khuu J.K., Dang C.Y., Hu J., Tran K.V., Liu A., Gomez S., Zhang Z., Yi R., Scumpia P., Grigorian M. and Lowry W.E. (2014). Stem cell quiescence acts as a tumour suppressor in squamous tumours. Nat. Cell Biol. 16, 99-107.
121. Xin H.W., Hari D.M., Mullinax J.E., Ambe C.M., Koizumi T., Ray S., Anderson A.J., Wiegand G.W., Garfield S.H., Thorgeirsson S.S. and Avital I. (2012). Tumor-initiating label-retaining cancer cells in human gastrointestinal cancers undergo asymmetric cell division. Stem Cells 30, 591-598.
122. Yang Z.J. and Wechsler-Reya R.J. (2007). Hit 'em where they live: Targeting the cancer stem cell niche. Cancer Cell 11, 3-5.
123. Yu M., Stott S., Toner M., Maheswaran S. and Haber D.A. (2011). Circulating tumor cells: Approaches to isolation and characterization. J. Cell Biol. 192, 373-382.
124. Yu M., Bardia A., Wittner B.S., Stott S.L., Smas M.E., Ting D.T., Isakoff S.J., Ciciliano J.C., Wells M.N., Shah A.M., Concannon K.F., Donaldson M.C., Sequist L.V., Brachtel E., Sgroi D., Baselga J., Ramaswamy S., Toner M., Haber D.A. and Maheswaran S. (2013). Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580-584.
125. Zhang S., Balch C., Chan M.W., Lai H.C., Matei D., Schilder J.M., Yan P.S., Huang T.H. and Nephew K.P. (2008). Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68, 4311-4320.
126. Zhang S.S., Han Z.P., Jing Y.Y., Tao S.F., Li T.J., Wang H., Wang Y., Li R., Yang Y., Zhao X., Xu X.D., Yu E.D., Rui Y.C., Liu H.J., Zhang L. and Wei L.X. (2012). Cd133(+)cxcr4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med. 10, 85.
127. Zhe X., Cher M.L. and Bonfil R.D. (2011). Circulating tumor cells: Finding the needle in the haystack. Am. J. Cancer Res. 1, 740-751.